-
2024-513976-16-00
5
2015-06-26
squamous cell carcinomas of the larynx or hypopharynx locally advance
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-514904-14-00
4
2014-10-08
Patients with metastatic or unresectable locally advanced malignancies
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-515171-35-00
5
2011-07-06
Prostatic adenocarnicoma with high risk of recurrence
-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2024-517254-99-00
4
2025-09-16
The patients enrolled in IMMUNORARE will be adult patients with 5 rar
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2023-510559-41-00
4
2025-01-02
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2025-521029-34-00
4
2025-09-18
Patients with overt hepatic encephalopathy (OHE) and acute decompensat
-
2024-515264-31-00
3
2025-04-15
PSMA-positive non-curative metastatic castration-resistant prostate ca
-
2024-513697-22-00
5
2024-11-07
non-small-cell lung cancer
-
2024-513647-86-00
4
2024-09-09
Patients displaying a non-classified, severe and resistant inflammator
-
2023-505903-22-00
4
2024-07-02
Sepsis associated acute kidney injury
-
2023-507324-23-00
4
2024-05-22
recurrent or persistent uterine serous carcinoma
-
2023-505083-11-01
4
2024-05-07
Alzheimer's Disease
-
2023-506707-25-00
5
2024-04-09
Choroidal neovascularization secondary to pathologic myopia
-
2023-505022-34-00
4
2024-03-27
Neoplasm malignant
-
2022-502584-38-00
5
2023-12-12
Locally advanced squamous cell carcinoma of the head and neck
-
2023-503270-20-00
3
2023-11-29
recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
-
2022-502372-22-01
4
2023-10-19
Metastatic Breast Cancer HR+, HER2-
-
2023-509833-38-00
5
2023-09-20
Birch Pollen-induced Allergic Rhinoconjunctivitis